BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019

BERGEN, Norway, Dec. 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will today provide an update from the Company's phase II study of bemcentinib (BGB324), a...

from PR Newswire: https://ift.tt/355IwIT